Guidance on Evaluating Impact of Viral Mutations on COVID-19 Tests and Lessons Learned Thus Far
Guidance on Evaluating Impact of Viral Mutations on COVID-19 Tests and Lessons Learned Thus Far
Image
As part of our March 18 COVID-19 Diagnostics Evidence Accelerator Collaborative meeting, Dr. Timothy Stenzel, Director of FDA’s Office of In Vitro Diagnostics and Radiological Health detailed the impact of viral mutations on COVID-19 testing and answered key questions posed by meeting participants.